Rosetta Genomics to Host 2016 First Quarter Financial Results and Business Update Conference Call on May 19, 2016
16 May 2016 - 10:00PM
Business Wire
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and
provider of microRNA-based and other molecular diagnostics, today
announced that the Company will file its financial results for the
three months ended March 31, 2016 on Form 6K with the U.S.
Securities and Exchange Commission (“SEC”) before the opening of
the U.S. financial markets on May, 19, 2016. The Form 6K will
include unaudited consolidated financial statements, as well as
additional information regarding the Company. The Form 6K will be
available at www.sec.gov and at www.rosettagenomics.com.
Kenneth A. Berlin, President and Chief Executive Officer of
Rosetta Genomics, and Ron Kalfus, Chief Financial Officer of
Rosetta Genomics, will host a conference call on Thursday, May 19,
2016 at 10:00 a.m. Eastern time to provide an update on the
Company’s business and respond to questions.
Individuals interested in listening to the conference call may
do so by dialing (866) 239-5859, or for international callers (702)
495-1913. The conference ID number is 12008886. The call is also
being webcast, and can be accessed on the investor relations
section of the Company’s website at www.rosettagx.com.
A telephone replay will be available through March 29, 2016 by
dialing (855) 859-2056 or for international callers (404) 537-3406,
and entering the Conference ID number 12008886. The webcast will be
available on the Company’s website for 30 days following the
completion of the call.
About Rosetta Genomics
Rosetta develops and commercializes a full range of
microRNA-based and other molecular diagnostics. Rosetta’s
integrative research platform combining bioinformatics and
state-of-the-art laboratory processes has led to the discovery of
hundreds of biologically validated novel human microRNAs. Building
on its strong patent position and proprietary platform
technologies, Rosetta is working on the application of these
technologies in the development and commercialization of a full
range of microRNA-based diagnostic tools. Through the acquisition
of PersonalizeDx, the Company now offers core FISH, IHC and
PCR-based testing capabilities and partnerships in Pathology,
Oncology and Urology that provide additional content and platforms
that complement Rosetta’s microRNA and Next-Gen Sequencing
offerings. RosettaGX Reveal™, a Thyroid microRNA Classifier for the
diagnosis of indeterminate thyroid FNA smears, as well as the full
RosettaGX™ portfolio of cancer testing services are commercially
available through the Company’s Philadelphia, PA- and Lake Forest,
CA-based CAP-accredited, CLIA-certified labs,. For more information
visit www.rosettagx.com.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future
expectations, plans and prospects constitute forward-looking
statements for the purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by these forward-looking
statements as a result of various important factors, including
those risks more fully discussed in the "Risk Factors" section of
Rosetta’s most recently filed Annual Report on Form 20-F, as filed
with the SEC. In addition, any forward-looking statements represent
Rosetta’s views only as of the date of this release and should not
be relied upon as representing its views as of any subsequent date.
Rosetta does not assume any obligation to update any
forward-looking statements unless required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160516005474/en/
Rosetta GenomicsKen Berlin, 267-298-1159President &
CEOinvestors@rosettagenomics.comorRosetta Genomics
InvestorsLHAAnne Marie Fields, 212-838-3777afields@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Apr 2024 to May 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From May 2023 to May 2024